RVMD
Revolution Medicines, Inc. [RVMD] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
RVMD Stock Summary
Top 10 Correlated Stocks
RVMD
In the News
RVMD Financial details
Company Rating
Neutral
Market Cap
5.94B
Income
-426.78M
Revenue
11.58M
Book val./share
12.93
Cash/share
13.12
Dividend
-
Dividend %
-
Employees
378
Optionable
No
Shortable
Yes
Earnings
06 May 2024
P/E
-9.68
Forward P/E
-
PEG
-5.05
P/S
178.52
P/B
3.72
P/C
2.73
P/FCF
-15.57
Quick Ratio
9.51
Current Ratio
9.64
Debt / Equity
0.05
LT Debt / Equity
0.04
-
-
EPS (TTM)
-3.67
EPS next Y
-
EPS next Q
-
EPS this Y
25.32%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
36.65%
Revenue last 5Y
-25.38%
Revenue Q/Q
-
EPS Q/Q
15.15%
-
-
-
-
SMA20
10.56%
SMA50
23.15%
SMA100
68.07%
Inst Own
70.52%
Inst Trans
0.6%
ROA
-33%
ROE
-38%
ROC
-0.41%
Gross Margin
100%
Oper. Margin
-1410%
Profit Margin
-1230%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
15.44-38.73
52W High
-5.71%
52W Low
+138.87%
RSI
60.93
Rel Volume
0.74
Avg Volume
1.43M
Volume
1.06M
Perf Week
8.61%
Perf Month
16.03%
Perf Quarter
79.06%
Perf Half Y
11.59%
-
-
-
-
Beta
1.539
-
-
Volatility
0.58%, 2.17%
Prev Close
-2.69%
Price
35.83
Change
-1.81%
RVMD Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.85 | 0.65 | 0.4 | 0.44 | 0.1 | |
| Net income per share | -0.81 | -1.62 | -2.47 | -3.08 | -3.86 | |
| Operating cash flow per share | -0.84 | -1.5 | -2.02 | -2.78 | -3.1 | |
| Free cash flow per share | -0.88 | -1.55 | -2.11 | -2.92 | -3.17 | |
| Cash per share | 2.08 | 6.62 | 7.93 | 8 | 16.38 | |
| Book value per share | 2.59 | 7.13 | 8.28 | 8.5 | 16.14 | |
| Tangible book value per share | 1.29 | 5.99 | 7.25 | 7.59 | 15.5 | |
| Share holders equity per share | 2.59 | 7.13 | 8.28 | 8.5 | 16.14 | |
| Interest debt per share | 0.03 | 0.49 | 0.92 | 0.68 | 0.78 | |
| Market cap | 1.71B | 2.64B | 1.83B | 1.92B | 3.25B | |
| Enterprise value | 1.69B | 2.57B | 1.79B | 1.82B | 2.64B | |
| P/E ratio | -35.77 | -24.38 | -10.19 | -7.72 | -7.44 | |
| Price to sales ratio | 34.07 | 61.34 | 62.35 | 54.28 | 280.24 | |
| POCF ratio | -34.37 | -26.35 | -12.45 | -8.56 | -9.26 | |
| PFCF ratio | -32.66 | -25.6 | -11.92 | -8.16 | -9.06 | |
| P/B Ratio | 11.18 | 5.55 | 3.04 | 2.8 | 1.78 | |
| PTB ratio | 11.18 | 5.55 | 3.04 | 2.8 | 1.78 | |
| EV to sales | 33.75 | 59.68 | 60.93 | 51.54 | 227.71 | |
| Enterprise value over EBITDA | -34.75 | -23.65 | -9.57 | -7.32 | -5.52 | |
| EV to operating cash flow | -34.03 | -25.63 | -12.17 | -8.13 | -7.52 | |
| EV to free cash flow | -32.35 | -24.9 | -11.65 | -7.75 | -7.36 | |
| Earnings yield | -0.03 | -0.04 | -0.1 | -0.13 | -0.13 | |
| Free cash flow yield | -0.03 | -0.04 | -0.08 | -0.12 | -0.11 | |
| Debt to equity | 0.01 | 0.07 | 0.11 | 0.09 | 0.05 | |
| Debt to assets | 0.01 | 0.06 | 0.09 | 0.08 | 0.04 | |
| Net debt to EBITDA | 0.34 | 0.66 | 0.22 | 0.39 | 1.27 | |
| Current ratio | 3.11 | 9.63 | 30.48 | 10.65 | 13.06 | |
| Interest coverage | -510.57 | -1.56K | -15.67K | 26.75 | -1.61K | |
| Income quality | 1.04 | 0.93 | 0.79 | 0.9 | 0.8 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.25 | 0.5 | 1.04 | 1.15 | 6.53 | |
| Research and developement to revenue | 1.83 | 3.08 | 6.36 | 7.15 | 36.01 | |
| Intangibles to total assets | 0.35 | 0.13 | 0.1 | 0.09 | 0.03 | |
| Capex to operating cash flow | 0.05 | 0.03 | 0.04 | 0.05 | 0.02 | |
| Capex to revenue | -0.05 | -0.07 | -0.22 | -0.31 | -0.67 | |
| Capex to depreciation | -0.77 | -0.45 | -0.89 | -1.12 | -0.83 | |
| Stock based compensation to revenue | 0.06 | 0.21 | 0.71 | 0.88 | 5.33 | |
| Graham number | 6.86 | 16.14 | 21.44 | 24.29 | 37.42 | |
| ROIC | -0.32 | -0.2 | -0.25 | -0.32 | -0.24 | |
| Return on tangible assets | -0.33 | -0.22 | -0.27 | -0.34 | -0.22 | |
| Graham Net | 1.04 | 5.3 | 6.04 | 6.47 | 14.07 | |
| Working capital | 90.93M | 406.95M | 558.12M | 598.2M | 1.74B | |
| Tangible asset value | 75.91M | 399.12M | 528.08M | 611.77M | 1.75B | |
| Net current asset value | 65.99M | 361.4M | 441.63M | 533.44M | 1.62B | |
| Invested capital | 0.01 | 0.07 | 0.11 | 0.09 | 0.05 | |
| Average receivables | 8.02M | 7.57M | 6.16M | 5.3M | 2.96M | |
| Average payables | 8.32M | 12M | 13.33M | 17.68M | 41.55M | |
| Average inventory | 3.3M | 0.5 | -6.36M | -6.36M | 0.5 | |
| Days sales outstanding | 63.73 | 54.29 | 73.63 | 48.21 | 39.53 | |
| Days payables outstanding | 45.35 | 34.8 | 699.78 | 805.37 | 2.42K | |
| Days of inventory on hand | 0 | 0 | -633.17 | 0 | 0 | |
| Receivables turnover | 5.73 | 6.72 | 4.96 | 7.57 | 9.23 | |
| Payables turnover | 8.05 | 10.49 | 0.52 | 0.45 | 0.15 | |
| Inventory turnover | 91.76M | 0 | -0.58 | 9.66M | 0 | |
| ROE | -0.31 | -0.23 | -0.3 | -0.36 | -0.24 | |
| Capex per share | -0.04 | -0.04 | -0.09 | -0.13 | -0.07 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q3
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.17 | 0.07 | 0.04 | 0 | 0.01 | |
| Net income per share | -0.63 | -0.62 | -0.92 | -0.99 | -1.14 | |
| Operating cash flow per share | -0.69 | -0.66 | -0.63 | -0.92 | -0.85 | |
| Free cash flow per share | -0.73 | -0.68 | -0.64 | -0.94 | -0.87 | |
| Cash per share | 7.23 | 9.59 | 8.51 | 7.44 | 13.12 | |
| Book value per share | 7.69 | 10.04 | 8.71 | 7.67 | 12.93 | |
| Tangible book value per share | 6.86 | 9.27 | 8.03 | 7 | 12.42 | |
| Share holders equity per share | 7.69 | 10.04 | 8.71 | 7.67 | 12.93 | |
| Interest debt per share | 0.68 | 0.57 | 0.59 | 0.58 | 0.69 | |
| Market cap | 2.12B | 2.05B | 2.86B | 3.02B | 4.05B | |
| Enterprise value | 2.03B | 1.69B | 2.54B | 2.73B | 3.44B | |
| P/E ratio | -9.4 | -8.78 | -7.27 | -6.97 | -6.27 | |
| Price to sales ratio | 138.54 | 292.85 | 747.69 | 0 | 5.46K | |
| POCF ratio | -34.37 | -32.92 | -42.6 | -30.09 | -33.59 | |
| PFCF ratio | -32.84 | -32.02 | -41.9 | -29.35 | -32.95 | |
| P/B Ratio | 3.1 | 2.16 | 3.07 | 3.61 | 2.22 | |
| PTB ratio | 3.1 | 2.16 | 3.07 | 3.61 | 2.22 | |
| EV to sales | 132.2 | 241.01 | 664.77 | 0 | 4.64K | |
| Enterprise value over EBITDA | -35.79 | -22.49 | -23.37 | -22.13 | -19.43 | |
| EV to operating cash flow | -32.8 | -27.09 | -37.87 | -27.15 | -28.54 | |
| EV to free cash flow | -31.34 | -26.35 | -37.25 | -26.48 | -28 | |
| Earnings yield | -0.03 | -0.03 | -0.03 | -0.04 | -0.04 | |
| Free cash flow yield | -0.03 | -0.03 | -0.02 | -0.03 | -0.03 | |
| Debt to equity | 0.09 | 0.07 | 0.07 | 0.08 | 0.05 | |
| Debt to assets | 0.08 | 0.06 | 0.06 | 0.06 | 0.04 | |
| Net debt to EBITDA | 1.72 | 4.84 | 2.91 | 2.4 | 3.43 | |
| Current ratio | 10.65 | 16.89 | 11.81 | 9.64 | 13.06 | |
| Interest coverage | 19.23 | 7.84 | 0 | 0 | -19.38 | |
| Income quality | 1.09 | 0.92 | 0.68 | 0.93 | 0.75 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.71 | 1.89 | 3.83 | 0 | 43.46 | |
| Research and developement to revenue | 4.31 | 9.83 | 25.62 | 0 | 197.93 | |
| Intangibles to total assets | 0.09 | 0.07 | 0.07 | 0.07 | 0.03 | |
| Capex to operating cash flow | 0.05 | 0.03 | 0.02 | 0.03 | 0.02 | |
| Capex to revenue | -0.19 | -0.25 | -0.29 | 0 | -3.12 | |
| Capex to depreciation | -1.11 | -0.69 | -0.63 | -1.18 | -0.81 | |
| Stock based compensation to revenue | 0.54 | 1.38 | 3.39 | 0 | 34.27 | |
| Graham number | 10.47 | 11.81 | 13.42 | 13.09 | 18.25 | |
| ROIC | -0.08 | -0.06 | -0.1 | -0.13 | -0.09 | |
| Return on tangible assets | -0.08 | -0.06 | -0.1 | -0.12 | -0.08 | |
| Graham Net | 5.85 | 8.35 | 7.19 | 6.1 | 11.27 | |
| Working capital | 598.2M | 868.12M | 844.03M | 738.93M | 1.74B | |
| Tangible asset value | 611.77M | 879.07M | 857.95M | 764.84M | 1.75B | |
| Net current asset value | 533.44M | 801.72M | 779.22M | 677.69M | 1.62B | |
| Invested capital | 0.09 | 0.07 | 0.07 | 0.08 | 0.05 | |
| Average receivables | 4.81M | 4.33M | 3.25M | 1.41M | 781.5K | |
| Average payables | 22.84M | 20.61M | 24.85M | 29.71M | 45.71M | |
| Average inventory | 1 | 0.5 | 0.5 | 1 | 0.5 | |
| Days sales outstanding | 27.43 | 51.26 | 59.07 | 0 | 152.1 | |
| Days payables outstanding | 737.8 | 707.49 | 1.51K | 1.24K | 1.95K | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 3.28 | 1.76 | 1.52 | 0 | 0.59 | |
| Payables turnover | 0.12 | 0.13 | 0.06 | 0.07 | 0.05 | |
| Inventory turnover | 2.6M | 0 | 1.77M | 2.15M | 0 | |
| ROE | -0.08 | -0.06 | -0.11 | -0.13 | -0.09 | |
| Capex per share | -0.03 | -0.02 | -0.01 | -0.02 | -0.02 |
RVMD Frequently Asked Questions
What is Revolution Medicines, Inc. stock symbol ?
Revolution Medicines, Inc. is a US stock , located in Redwood city of Ca and trading under the symbol RVMD
What is Revolution Medicines, Inc. stock quote today ?
Revolution Medicines, Inc. stock price is $35.83 today.
Is Revolution Medicines, Inc. stock public?
Yes, Revolution Medicines, Inc. is a publicly traded company.
Company Profile
- Volume Average 1.43M
- Market Capitalization 5.94B
- Employee 378
- CEO Dr. Mark A. Goldsmith Ph.D.
- Headquarters Redwood City,CA,US
- IPO Date 2020-02-13
-
Website
https://www.revmed.com 
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
